1114333-11-7

Basic information

• Product Name: (S)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE-HCl
• Synonyms: (S)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE-HCl;(S)-5-Fluoro-2,3-dihydro-1H-inden-1-aMine hydrochloride
• CAS NO: 1114333-11-7
• Molecular Formula: C9H11ClFN
• Molecular Weight: 187.6417432
• Mol File: 1114333-11-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 222.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.160±0.06 g/cm3(Predicted)
• PKA: 9.16±0.20(Predicted)
• CAS DataBase Reference: (S)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE-HCl(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE-HCl(1114333-11-7)
• EPA Substance Registry System: (S)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE-HCl(1114333-11-7)

Safety Data

• Hazardous Substances Data: 1114333-11-7(Hazardous Substances Data)

Usage

General Description

(S)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE-HCl is a chemical compound that consists of a fluorinated indene moiety and an amine functional group. The HCl in its name indicates that it is a hydrochloride salt. (S)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE-HCl may have potential pharmaceutical applications, as indene derivatives have been investigated for their pharmacological properties, including anti-inflammatory and analgesic effects. The specific properties and potential uses of (S)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE-HCl would need to be further studied and characterized in order to fully understand its potential value in various applications.

InChI:InChI=1S/C9H10FN.ClH/c10-7-2-3-8-6(5-7)1-4-9(8)11;/h2-3,5,9H,1,4,11H2;1H/t9-;/m0./s1

Upstream product

• 148960-33-2 5-fluoro-2,3-dihydro-1H-inden-1-amine 
• 700-84-5 5-fluoro-1-indanone 
• 7440-66-6 zinc 
• 148960-32-1 5-fluoro-1-indanone oxime 

Relevant articles and documents

CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.